DGX · Quest Diagnostics Incorporated
$235.02
+1.68% last session
End-of-day data · close of 2026-09-11
Market cap
$26B
Enterprise value
$32B
Trailing P/E
24.5
Forward P/E
19.2
Dividend yield
1.0%
Beta
0.55
Avg volume
1M
Employees
46K
Daily Change %
1.68%
5 Days Change
-0.71%
10 Days Change
-2.01%
30 Days Change
-0.86%
60 Days Change
13.51%
Month to Day Change
-0.32%
Year to Day Change
37.46%
Analyst Outlook
Analyst estimates change daily — follow the shifts on the Estimate Trends page.
Technical Analysis
Analyst sentiment over time — DGX
Rec Mean (blue, left — higher = more bullish) vs. price targets (right).
Investment Bank Ratings as of 2026-09-08
Latest call per bank · past 12 months
UBS
Neutral$245
+6.0% vs priceJP Morgan
Neutral$250
+8.2% vs priceBarclays
Overweight$250
+8.2% vs priceJefferies
Buy$220
-4.8% vs priceCitigroup
Neutral$215
-7.0% vs priceRecent rating actions
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-09-08 | UBS | Maintains | Neutral | $232 → $245 |
| 2026-07-28 | JP Morgan | Maintains | Neutral | $220 → $250 |
| 2026-07-25 | UBS | Maintains | Neutral | $220 → $232 |
| 2026-07-24 | Mizuho | Maintains | Outperform | $235 → $260 |
| 2026-07-24 | Truist Securities | Maintains | Hold | $225 → $250 |
| 2026-07-24 | Barclays | Maintains | Overweight | $230 → $250 |
| 2026-07-24 | Baird | Maintains | Neutral | $236 → $255 |
| 2026-07-13 | Baird | Maintains | Neutral | $232 → $236 |
Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.
Signal Summary as of 2026-09-11
- RSI (14): RSI is 49 — neutral momentum, neither overbought nor oversold.
- Price vs 50-day MA: Trading 2.5% above the 50-day MA ($229.22).
- Price vs 200-day MA: Trading 17.0% above the 200-day MA ($200.92).
- MA cross: The 50-day MA sits above the 200-day MA (golden-cross regime) — the longer-term trend points up.
- MACD (12,26,9): MACD histogram is negative (-1.83) — short-term momentum is fading.
- 52-week range: Price is within 5% of the 52-week high ($245.00).
DGX Price Chart
Loading chart for DGX…
Fundamentals
About Quest Diagnostics Incorporated
Quest Diagnostics Incorporated provides diagnostic testing and services in the United States. The company develops and delivers diagnostic information services, such as routine, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services. It also provides services under the Quest Diagnostics brand, as well as under the AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum brands to physicians, hospitals, patients and consumers, health plans, government agencies, employers, retailers, pharmaceutical companies and insurers commercial clinical laboratories, and accountable care organizations through a network of laboratories, patient service centers, phlebotomists in physician offices, call centers and mobile phlebotomists, nurses, and other health and wellness professionals. In addition, the company offers risk assessment services for the life insurance industry; healthcare IT healthcare providers and payers; testing and medical director services at hospital laboratories; test offerings in cardiometabolic and endocrine; cancer; clinical drug monitoring and toxicology; infectious disease, including autoimmune; neurology diagnostics, including Alzheimer's disease; and women's health, such as prenatal genetic; workplace drug testing, testing urine, hair, and oral fluid specimens services; and employer population health services, including biometric screenings, flu shots, and related preventative services. Further, it provides population health solutions; extended care services; develops in vitro diagnostic tests; laboratory diagnostic information and digital health connectivity systems; underwriting support services, including data gathering, paramedical examinations, and clinical laboratory testing and analytics; and national specimen collection and health data solutions. Quest Diagnostics Incorporated was founded in 1967 and is headquartered in Secaucus, New Jersey.
More in Diagnostics & Research
Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.